Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis

References

1. 1.↵
   2. Ricard D,
   3. Idbaih A,
   4. Ducray F, et al

   . Primary brain tumours in adults. Lancet 2012;379:1984–96 doi:10.1016/S0140-6736(11)61346-9 pmid:22510398

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Wen PY,
   3. Macdonald DR,
   4. Reardon DA, et al

   . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

   Abstract/FREE Full Text
3. 3.↵
   2. van den Bent MJ,
   3. Wefel JS,
   4. Schiff D, et al

   . Response Assessment in Neuro-Oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12:583–93 doi:10.1016/S1470-2045(11)70057-2 pmid:21474379

   CrossRefPubMedWeb of Science
4. 4.↵
   2. De Witt Hamer PC,
   3. Robles SG,
   4. Zwinderman AH, et al

   . Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 2012;30:2559–65 doi:10.1200/JCO.2011.38.4818 pmid:22529254

   Abstract/FREE Full Text
5. 5.↵
   2. Sanai N,
   3. Polley MY,
   4. McDermott MW, et al

   . An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3–8 doi:10.3171/2011.2.JNS10998 pmid:21417701

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Capelle L,
   3. Fontaine D,
   4. Mandonnet E, et al

   ; French Réseau d'Étude des Gliomes. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg 2013;118:1157–68 doi:10.3171/2013.1.JNS121 pmid:23495881

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Einstein DB,
   3. Wessels B,
   4. Bangert B, et al

   . Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012;84:668–74 doi:10.1016/j.ijrobp.2012.01.020 pmid:22445005

   CrossRefPubMed
8. 8.↵
   2. Smith JS,
   3. Chang EF,
   4. Lamborn KR, et al

   . Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26:1338–45 doi:10.1200/JCO.2007.13.9337 pmid:18323558

   Abstract/FREE Full Text
9. 9.↵
   2. Pichlmeier U,
   3. Bink A,
   4. Schackert G, et al

   ; ALA Glioma Study Group. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008;10:1025–34 doi:10.1215/15228517-2008-052 pmid:18667747

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Pallud J,
    3. Varlet P,
    4. Devaux B, et al

    . Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology 2010;74:1724–31 doi:10.1212/WNL.0b013e3181e04264 pmid:20498440

    CrossRefPubMed
11. 11.↵
    2. Kelly PJ,
    3. Daumas-Duport C,
    4. Kispert DB, et al

    . Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66:865–74 doi:10.3171/jns.1987.66.6.0865 pmid:3033172

    CrossRefPubMedWeb of Science
12. 12.↵
    2. la Fougère C,
    3. Suchorska B,
    4. Bartenstein P, et al

    . Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol 2011;13:806–19 doi:10.1093/neuonc/nor054 pmid:21757446

    CrossRefPubMed
13. 13.↵
    2. Waldman AD,
    3. Jackson A,
    4. Price SJ, et al

    ; National Cancer Research Institute Brain Tumour Imaging Subgroup. Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol 2009;6:445–54 doi:10.1038/nrclinonc.2009.92 pmid:19546864

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Landis JR,
    3. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 doi:10.2307/2529310 pmid:843571

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Bossuyt PM,
    3. Reitsma JB,
    4. Bruns DE, et al

    ; STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 2015;277:826–32 doi:10.1148/radiol.2015151516 pmid:26509226

    CrossRefPubMed
16. 16.↵
    2. Rutter CM,
    3. Gatsonis CA

    . A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001;20:2865–84 doi:10.1002/sim.942 pmid:11568945

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Glas AS,
    3. Lijmer JG,
    4. Prins MH, et al

    . The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129–35 doi:10.1016/S0895-4356(03)00177-X pmid:14615004

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Macaskill P

    . Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. J Clin Epidemiol 2004;57:925–32 doi:10.1016/j.jclinepi.2003.12.019 pmid:15504635

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Harbord RM,
    3. Whiting P,
    4. Sterne JA, et al

    . An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008;61:1095–103 doi:10.1016/j.jclinepi.2007.09.013 pmid:19208372

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Riley RD,
    3. Dodd SR,
    4. Craig JV, et al

    . Meta-analysis of diagnostic test studies using individual patient data and aggregate data. Stat Med 2008;27:6111–36 doi:10.1002/sim.3441 pmid:18816508

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Sutton AJ,
    3. Kendrick D,
    4. Coupland CA

    . Meta-analysis of individual- and aggregate-level data. Stat Med 2008;27:651–69 doi:10.1002/sim.2916 pmid:17514698

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Dukic V,
    3. Gatsonis C

    . Meta-analysis of diagnostic test accuracy assessment studies with varying number of thresholds. Biometrics 2003;59:936–46 doi:10.1111/j.0006-341X.2003.00108.x pmid:14969472

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Leeflang MM,
    3. Deeks JJ,
    4. Gatsonis C, et al

    ; Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008;149:889–97 doi:10.7326/0003-4819-149-12-200812160-00008 pmid:19075208

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Rutjes AW,
    3. Reitsma JB,
    4. Di Nisio M, et al

    . Evidence of bias and variation in diagnostic accuracy studies. CMAJ 2006;174:469–76 doi:10.1503/cmaj.050090 pmid:16477057

    Abstract/FREE Full Text
25. 25.↵
    2. Chou R,
    3. Cuevas C,
    4. Fu R, et al

    . Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med 2015;162:697–711 doi:10.7326/M14-2509 pmid:25984845

    CrossRefPubMed
26. 26.↵
    2. Silvestri GA,
    3. Gonzalez AV,
    4. Jantz MA, et al

    . Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed—American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e211S–50S doi:10.1378/chest.12-2355 pmid:23649440

    CrossRefPubMed
27. 27.↵
    2. Zhang Y,
    3. Qin Q,
    4. Li B, et al

    . Magnetic resonance imaging for N staging in non-small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer 2015;6:123–32 doi:10.1111/1759-7714.12203 pmid:26273348

    CrossRefPubMed
28. 28.↵
    2. Peters NH,
    3. Borel Rinkes IH,
    4. Zuithoff NP, et al

    . Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 2008;246:116–24 doi:10.1148/radiol.2461061298 pmid:18024435

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Lemée JM,
    3. Clavreul A,
    4. Aubry M, et al

    . Characterizing the peritumoral brain zone in glioblastoma: a multidisciplinary analysis. J Neurooncol 2015;122:53–61 doi:10.1007/s11060-014-1695-8 pmid:25559687

    CrossRefPubMed
30. 30.↵
    2. Kros JM,
    3. Gorlia T,
    4. Kouwenhoven MC, et al

    . Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007;66:545–51 doi:10.1097/01.jnen.0000263869.84188.72 pmid:17549014

    CrossRefPubMed
31. 31.↵
    2. Scott CB,
    3. Nelson JS,
    4. Farnan NC, et al

    . Central pathology review in clinical trials for patients with malignant glioma: a report of Radiation Therapy Oncology Group 83–02. Cancer 1995;76:307–13 pmid:8625107

    CrossRefPubMedWeb of Science
32. 32.↵
    2. van den Bent MJ

    . Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 2010;120:297–304 doi:10.1007/s00401-010-0725-7 pmid:20644945

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Bjartmarz H,
    3. Rehncrona S

    . Comparison of accuracy and precision between frame-based and frameless stereotactic navigation for deep brain stimulation electrode implantation. Stereotact Funct Neurosurg 2007;85:235–42 doi:10.1159/000103262 pmid:17534136

    CrossRefPubMed
34. 34.↵
    2. Zacest A,
    3. Berk C,
    4. Burchiel KJ

    . Precision and accuracy of stereotactic targeting in patients undergoing repeat stereotactic surgery. Stereotact Funct Neurosurg 2009;87:168–73 doi:10.1159/000215932 pmid:19420985

    CrossRefPubMed
35. 35.↵
    2. Sottoriva A,
    3. Spiteri I,
    4. Piccirillo SG, et al

    . Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 2013;110:4009–14 doi:10.1073/pnas.1219747110 pmid:23412337

    Abstract/FREE Full Text
36. 36.↵
    2. Zhao F,
    3. Li M,
    4. Kong L, et al

    . Delineation of radiation therapy target volumes for patients with postoperative glioblastoma: a review. Onco Targets Ther 2016;9:3197–204 doi:10.2147/OTT.S104241pmid:27313465

    CrossRefPubMed
37. 37.↵
    2. Niyazi M,
    3. Brada M,
    4. Chalmers AJ, et al

    . ESTRO-ACROP guideline “target delineation of glioblastomas.” Radiother Oncol 2016;118:35–42 doi:10.1016/j.radonc.2015.12.003 pmid:26777122

    CrossRefPubMed
38. 38.↵
    2. Cabrera AR,
    3. Kirkpatrick JP,
    4. Fiveash JB, et al

    . Radiation therapy for glioblastoma: executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 2016;6:217–25 doi:10.1016/j.prro.2016.03.007 pmid:27211230

    CrossRefPubMed
39. 39.↵
    2. Albert NL,
    3. Weller M,
    4. Suchorska B, et al

    . Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 2016;18:1199–208 doi:10.1093/neuonc/now058 pmid:27106405

    CrossRefPubMed
40. 40.↵
    2. Fink JR,
    3. Muzi M,
    4. Peck M, et al

    . Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging. J Nucl Med 2015;56:1554–61 doi:10.2967/jnumed.113.131516 pmid:26294301

    Abstract/FREE Full Text
41. 41.↵
    2. Langen KJ,
    3. Galldiks N,
    4. Hattingen E, et al

    . Advances in neuro-oncology imaging. Nat Rev Neurol 2017;13:279–89 doi:10.1038/nrneurol.2017.44 pmid:28387340

    CrossRefPubMed
42. 42.↵
    2. Brandão LA,
    3. Castillo M

    . Adult brain tumors: clinical applications of magnetic resonance spectroscopy. Magn Reson Imaging Clin N Am 2016;24:781–809 doi:10.1016/j.mric.2016.07.005 pmid:27742117

    CrossRefPubMed
43. 43.↵
    2. Kalpathy-Cramer J,
    3. Gerstner ER,
    4. Emblem KE, et al

    . Advanced magnetic resonance imaging of the physical processes in human glioblastoma. Cancer Res 2014;74:4622–37 doi:10.1158/0008-5472.CAN-14-0383 pmid:25183787

    Abstract/FREE Full Text
44. 44.↵
    2. Jain R,
    3. Gutierrez J,
    4. Narang J, et al

    . In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 2011;32:388–94 doi:10.3174/ajnr.A2280 pmid:21071537

    Abstract/FREE Full Text
45. 45.↵
    2. Pauleit D,
    3. Floeth F,
    4. Hamacher K, et al

    . O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678–87 doi:10.1093/brain/awh399 pmid:15689365

    CrossRefPubMedWeb of Science
46. 46.↵
    2. Lijmer JG,
    3. Bossuyt PMM,
    4. Heisterkamp SH

    . Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 2002;21:1525–37 doi:10.1002/sim.1185 pmid:12111918

    CrossRefPubMedWeb of Science